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Letter to the Editor
Planning and comparisons in clinical trials
H.E.M. Kay
Leukaemia Trials Office, (Medical Research Council), Chester Beatty Research Institute, Institutefor Cancer
Research, Fulham Road, London, SW3 6JB.
Sir-The conduct and interpretation of clinical trials have provoked a voluminous discussion in books and
journals. The leukaemia trials organised by the Medical Research Council have been no exception and have,
among other things, generated a lengthy article by a group of eminent statisticians with strongly held
opinions (Peto et al., 1976-1977). That article has been widely quoted and is a valuable corrective to some
mistaken views about trials but it does not tell the whole story. This letter represents the views of a trial co-
ordinator and is, as such, supplementary to, but in parts divergent from, the views of the statisticians. Insofar
as there are divergences they ghould be regarded in part as evidence of active thought and dialogue by all
concerned and in part because views of any subject naturally evolve and change. Indeed a few of the
arguments put forward in this paper have been touched on by Ciampi & Till (1980), but their very
mathematical approach to the topic may be less easily appreciated by many clinical oncologists who might
prefer my praginatic warp to their numerical woof.
Four points will be considered:
1. Consensus and randomisation in large multi-centre trials.
2. Treatment or treatment policy comparisons.
3. Cormparison with the previous best or standard treatment.
4. Measurables and unmeasurables.
1. Trial size, consensus and randomisation in large
multi-centre trials
One dilemma which has existed in the organisation
of the leukaemia trials, without ever being explicitly
stated, runs as follows. It is agreed that to achieve
significant differences it may be necessary to attract
a large entry of patients and that a large entry
necessitates a multi-centre trial, for which the
collaboration of many participants is needed.
However, it may be difficult or impossible to obtain
the agreement of a large group of well-informed
participants to any trial which proposes
randomisation to widely different forms of
treatment, even though there may be advocates for
each proposal among the participants. To maintain
participation by the majority, the best that can be
achieved may be a compromise regimen with
randomisation to treatments with differences of a
relatively trivial kind. Thus insistence on universal,
randomisation may either deter participation, or
lead to trials centred on trivial questions with the
consequence that the interesting comparisons can
only come from the results of successive trials (and
thus subject to secular bias) or through
comparisons with other groups. An alternative
compromise solution to this problem is the partly
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randomised trial. Examples of such trials which
have given useful 'results are the Concord Trial
(MRC 1971), where some but not all participants
agreed to include a "no further treatment" regimen
in the randomised allocation and thus helped to
disprove the value of BCG immunotherapy, and
UKALL I (MRC 1973) where CNS prophylaxis
was a randomised variable in 4 centres whereas the
remaining ceftres electively allocated all or none of
their patients to CNS prophylaxis.
Current examples of partly randomised trials are
in polycythaemia rubra vera and CLL in which
there are options for either a 'single regime or
randomisation to 2 or 3 arms. In some trials
practical considerations have prevented entry to
one arm of a trial, e.g. difficulties in giving
radiotherapy and intrathecal methotrexate
synchronously because the facilities and expertise
were not both available in one place; or the
restricted availability of immunotherapy in AML.
trials (MRC 1979). Obviously in these situations
there is a potential bias and comparisons have to be
interpreted with extra caution.
In UKALL VI and VII one variable has been the
use of prophylactic testicular irradiation and in
some centres an attempt has been made to
randomise this procedure. On the whole, however,
the choice has been determined after consultation
between physicians and parents or patients (which
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is essential to the procurement of informed
consent), but obviously in such cases the views of
the physician are reflected in the proportion given
irradiation.
The inclusion of non-randomised or semi-
randomised variables is, of course, sub-optimal in
some respects but, provided the basis of treatment
allocation is clearly stated, e.g. all cases at certain
centres have regimen X, provided the trials group
remains aware of the possibilities of resultant bias
and conveys that awareness to the reader of trial
reports, no harm is done.
Obviously extra caution is needed in the
interpretation of the trial results but such caution
should be instinctive since the opportunity for wide
divergence to occur by chance is always present,
even within a randomised controlled trial. This
became apparent in UKALL II where a clear
advantage was demonstrated for the omission of
cyclophosphamide from the maintenance schedule.
No stratification in randomisation, however, had
been used and it became clear that the difference
was largely due to the chance of allocation of more
girls to the "no cyclophosphamide" arm and more
boys to the "with cyclophosphamide" arm (MRC
1978).
Although systematic "centre" differences may
occur, and indeed are to be expected, there are
valuable checks on this possible bias through
having several centres to each arm, by having some
centres which do randomise and by careful scrutiny
of records to see whether differences in practice,
other than those of the variable concerned, have
occurred. In this way, the semi-randomised trial
provides the opportunity to make more important
and relevant comparisons than are possible in large
fully randomised trials where total agreement may
only be obtained on questions of secondary
importance. At the same time because the records
are standardised and analysed in one organisation
they are probably better "controlled" than other
inter-trial comparisons-valuable though the latter
may be. For example, in the field of CNS
prophylaxis current practice is largely influenced by
comparisons between groups (see Green et al.,
1980) rather than on any recent randomised
controlled study.
2. Comparing treatments or treatment policies
Strictly speaking, a clinical trial compares treatment
policies rather than treatments (Peto et al., 1976, p.
605), since what is done may differ for a number of
reasons, good or bad, from what is prescribed by
trial protocol. However, in many treatments, and
not least in the chemotherapy of malignant disease,
the degree to which a policy is implemented may
vary greatly according to the facilities available; the
experience, caution, and prejudices of the clinicians
concerned; the views of the patient and degree of
compliance; and perhaps most of all, the emphasis
mutually placed on the quality rather than duration
of life. This variation in policy implementation may
critically affect the outcome and hence the
interpretation of the results. Thus, in Myeloma III,
a relatively non-toxic but nauseating regime of
cyclophosphamide was compared with a relatively
myelotoxic regimen of melphalan and prednisone
(M+P) (MRC 1980).
The difference in aggregate results was
"insignificantly" small and marginally in favour of
M+P. Nevertheless, more detailed analysis,
including examination of a sample of the patients'
notes, revealed two important facts; firstly the
application of the two regimes varied widely from
centre to centre; and secondly, some patients
suffered severe myelotoxicity from the melphalan.
Thus the initial conclusion of "no significant
difference" had to be modified. My interpretation is
that melphalan was distinctly better if well-tolerated
but that in the presence of myelosuppression, either
before or after one course of melphalan,
cyclophosphamide was the preferred treatment. In
such circumstances it is imperative to analyse not
only the treatment policies as laid down in the
protocol, but the effects of actual treatments and
for that purpose a large amount of detail may be
needed. Since nearly all cancer therapy is pushed to
the limits of toxicity or tolerability in order to gain
the maximum effect, there will always be variation
in the way the treatment policy is implemented by
the physician and by the patient; thus it will seldom
be sufficient and may often be misleading to
compare merely the outcome of the, policies without
consideration of detailed information of the
treatment actually given and of toxic effects
experienced.
3. Comparison with previous best or "standard"
treatment
One tradition in the MRC leukaemia trials has
been to progress stepwise by comparing a new
treatment with a previous "best" treatment. This
sounds ideal but is beset with grave practical
difficulties.
In the first place, the increasing longevity of
remission and survival means that some years must
elapse before the previous "best" is actually known.
Although it may be suspected from the preliminary
results of the earliest entered cases, that may be a
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non-toxic regime gives better results in the short
run but not in the long run. Alternatively, if the
trend is later confirmed in the long run with more
patients, but a particular level of significance has
not yet been reached when the next trial is planned,
it is highly imprudent to reveal the inconclusive
results while the first trial is still in progress.
Secondly, it must be realised that any comparison
with a previous "best" regime is biased from the
outset by the fact that the participants have
experience of the previous regime but not of the
new one. The optimal administration of, say, a new
schedule of methotrexate dosage or the optimum
tempo for giving an AML remission-induction
regime, require experience at first hand which no
amount of advice or protocol instruction can
replace. Thus the early results of a regime may
have to be discounted until a comparable
experience is gained and a valid comparison
becomes possible. Once again, details of actual
treatments rather than a bare comparison of
treatment policies, is the essential guide to the
truth.
4. Measurables and unmeasurables
Theoretically, everything is measurable in some
way. In practice it is not. Some things can be
measured approximately and with difficulty, for
example the frequency of minor infections or
mouth soreness: some things can be estimated with
subjective bias such as the ease of monitoring a
regime and the desirable frequency of attendance
for blood-counts, dose adjustment etc.: but how can
one assess the misery or bloody-mindedness of a
child on treatment for ALL? How estimate the
distress caused by intravenous medication, alopecia,
or ketamine hallucinations? And how assess the net
gain and loss of a child's life saved at the expense
of some damage -to cerebral function? At best, only
approximations can be made whilst the summation
and comparison of all such approximations is a
highly subjective exercise. Nevertheless, these may
be amongst the most important considerations, in
assessing the consequences of treatment and in
comparing two different treatments.
At the same time, other parameters may be
measured with reasonable accuracy and the possible
limits of variation indicated with some precision as,
for example, by a standard deviation. The risk in
such circumstances is that the measurables will be
accorded a greater importance than the
unmeasurables, and a disproportionate attention is
paid to them. Any reputable statistician will deplore
the spurious accuracy of expressing, say, 4/7 as
57.14%, but may be less aware that the numerical
results he analyses are only a part of the whole
equation of benefit assessment and may, by over-
emphasis, be equally misleading.
One consequence is that the search for ever
greater numbers of cases to establish a higher
degree of significance for an observed difference
may be beside the point. If two treatments appear to
be approximately the same then, once the detailed
analysis of sub-sets has been completed, questions
on the importance and difference of the
unmeasurables must be put. Thereafter, the
emphasis they receive in a published report should
be equivalent to their importance and not to their
measurability. One consequence of this may be that
the major statistical analysis should be confined to
appendices.
Furthermore, we should recollect that the
question posed by most clinical trials is, as others
have pointed out, a pragmatic one (Schwartz et al.,
1980). It is not that "we wish to know from a
biological point of view whether a difference exists
or not" but "we require to choose one or other of
the treatments." Such an approach requires smaller
numbers of patients to each trial and is more
logically combined with the semi-measurable data
assembled by the trial participants, who are, (or let
all of us, who might one day be a patient, hope
that they are) pragmatists, one and all.
The opinions expressed in this letter are my own
and do not represent official policy of the MRC
Committees and Working Parties concerned with
leukaemia. Naturally, however, they are heavily
influenced by discussions with many colleagues
concerned in the MRC trials whose help I am
happy to acknowledge. I am particularly grateful to
Professor M.R. Alderson for detailed discussion.
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